Literature DB >> 31179503

Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.

Peter L Havens1, Suzanne E Perumean-Chaney2, Amit Patki2, Stacey S Cofield2, Craig M Wilson3, Nancy Liu4, Peter L Anderson5, Raphael J Landovitz6, Bill G Kapogiannis7, Sybil G Hosek8, Kathleen Mulligan9.   

Abstract

Human immunodeficiency virus-seronegative men aged 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation. Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP in participants aged 15-19 years. Clinical Trials Registration. NCT01772823 (ATN 110) and NCT01769456 (ATN 113).
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adolescents; bone mineral density; men who have sex with men; preexposure prophylaxis; tenofovir disoproxil fumarate

Mesh：

Substances：

Year:  2020        PMID： 31179503      PMCID： PMC7319267          DOI： 10.1093/cid/ciz486

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  24 in total

1.  Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.

Authors:  Roger Bedimo; Naim M Maalouf; Song Zhang; Henning Drechsler; Pablo Tebas
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Authors:  David V Glidden; Kathleen Mulligan; Vanessa McMahan; Peter L Anderson; Juan Guanira; Suwat Chariyalertsak; Susan P Buchbinder; Linda Gail Bekker; Mauro Schechter; Beatriz Grinsztejn; Robert M Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2017-10-01       Impact factor: 3.731

3.  Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Kathleen Mulligan; David V Glidden; Peter L Anderson; Albert Liu; Vanessa McMahan; Pedro Gonzales; Maria Esther Ramirez-Cardich; Sirianong Namwongprom; Piotr Chodacki; Laura Maria Carvalo de Mendonca; Furong Wang; Javier R Lama; Suwat Chariyalertsak; Juan Vicente Guanira; Susan Buchbinder; Linda-Gail Bekker; Mauro Schechter; Valdilea G Veloso; Robert M Grant
Journal:  Clin Infect Dis       Date:  2015-04-23       Impact factor: 9.079

4.  Low bone mineral density, regardless of HIV status, in men who have sex with men.

Authors:  Marlous L Grijsen; Saskia M E Vrouenraets; Ferdinand W N M Wit; Ineke G Stolte; Maria Prins; Paul Lips; Peter Reiss; Jan M Prins
Journal:  J Infect Dis       Date:  2012-11-12       Impact factor: 5.226

5.  Tracking of bone mass and density during childhood and adolescence.

Authors:  Heidi J Kalkwarf; Vicente Gilsanz; Joan M Lappe; Sharon Oberfield; John A Shepherd; Thomas N Hangartner; Xangke Huang; Margaret M Frederick; Karen K Winer; Babette S Zemel
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

6.  Effect of Vitamin D Supplementation on Bone Turnover Markers During HIV Pre-Exposure Prophylaxis Using Tenofovir Disoproxil Fumarate-Emtricitabine in Men Who Have Sex with Men.

Authors:  Deepa D Nanayakkara; Xiaoying Sun; Sheldon Morris; Stan Louie; Kathleen Mulligan; Turner Overton; Isaac Asante; Katya Corado; Sonia Jain; Michael P Dubé
Journal:  AIDS Res Hum Retroviruses       Date:  2019-05-08       Impact factor: 2.205

7.  Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.

Authors:  Peter L Havens; Ashutosh Tamhane; Charles B Stephensen; Gertrud U Schuster; Catherine M Gordon; Nancy Liu; Craig M Wilson; Sybil G Hosek; Peter L Anderson; Bill G Kapogiannis; Kathleen Mulligan
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-05       Impact factor: 2.205

8.  Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.

Authors:  Albert Y Liu; Eric Vittinghoff; Deborah E Sellmeyer; Risha Irvin; Kathleen Mulligan; Kenneth Mayer; Melanie Thompson; Robert Grant; Sonal Pathak; Brandon O'Hara; Roman Gvetadze; Kata Chillag; Lisa Grohskopf; Susan P Buchbinder
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

9.  Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.

Authors:  Brenda G Mirembe; Clifton W Kelly; Nyaradzo Mgodi; Susan Greenspan; James Y Dai; Ashley Mayo; Jeanna Piper; Carolyne A Akello; Flavia M Kiweewa; Tsitsi Magure; Clemensia Nakabiito; Jeanne M Marrazzo; Z Mike Chirenje; Sharon A Riddler
Journal:  J Acquir Immune Defic Syndr       Date:  2016-03-01       Impact factor: 3.731

10.  Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.

Authors:  Ella T Nkhoma; Lisa Rosenblatt; Joel Myers; Angelina Villasis-Keever; John Coumbis
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240
View more
  5 in total

1.  Tenofovir Alafenamide for HIV Preexposure Prophylaxis.

Authors:  Douglas S Krakower; Demetre C Daskalakis; Judith Feinberg; Julia L Marcus
Journal:  Ann Intern Med       Date:  2020-07-07       Impact factor: 25.391

2.  Vitamin D and Calcium Supplementation Reverses Tenofovir-Caused Bone Mineral Density Loss in People Taking ART or PrEP: A Systematic Review and Meta-Analysis.

Authors:  Xiaoyan Bi; Fan Liu; Xiangjun Zhang; Hongyi Wang; Zehao Ye; Ke Yun; Xiaojie Huang; Haibo Ding; Wenqing Geng; Junjie Xu
Journal:  Front Nutr       Date:  2022-03-31

3.  Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.

Authors:  Mary R Tanner; Peter Miele; Wendy Carter; Sheila Salvant Valentine; Richard Dunville; Bill G Kapogiannis; Dawn K Smith
Journal:  MMWR Recomm Rep       Date:  2020-04-24

Review 4.  Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate?

Authors:  Stephanie Shiau; Stephen M Arpadi; Michael T Yin
Journal:  Curr HIV/AIDS Rep       Date:  2020-02       Impact factor: 5.071

Review 5.  Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.

Authors:  Sheldon D Fields; Elyse Tung
Journal:  Infect Dis Ther       Date:  2021-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.